Bazzichetto Chiara, Milella Michele, Zampiva Ilaria, Simionato Francesca, Amoreo Carla Azzurra, Buglioni Simonetta, Pacelli Chiara, Le Pera Loredana, Colombo Teresa, Bria Emilio, Zeuli Massimo, Del Bufalo Donatella, Sperduti Isabella, Conciatori Fabiana
Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Medical Oncology 1, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Biomedicines. 2022 Oct 19;10(10):2631. doi: 10.3390/biomedicines10102631.
Among soluble actors that have emerged as druggable factors, the chemokine interleukin-8 (IL-8) has emerged as a possible determinant of response to immunotherapy and targeted treatment in several cancer types; however, its prognostic/predictive role in colorectal cancer (CRC) remains to be established. We: (i) conducted a systematic review of published literature on IL-8 expression in CRC; (ii) searched public transcriptomics databases; (iii) investigated IL-8 expression, by tumor and infiltrating cells, in a series of CRC samples; and (iv) carried out a meta-analysis of published literature correlating IL-8 expression and CRC prognosis. IL-8 possesses an important role as a mediator of the bidirectional crosstalk between tumor/stromal cells. Transcriptomic analysis indicated that specific IL-8 transcripts were significantly overexpressed in CRC compared to normal colon mucosa. Moreover, in our series we observed a statistically significant correlation between PTEN-loss and IL-8 expression by infiltrating mononuclear and tumor cells. In total, 12 papers met our meta-analysis inclusion criteria, demonstrating that high IL-8 levels significantly correlated with shorter overall survival and progression-free survival. Sensitivity analysis demonstrated a highly significant correlation with outcome for circulating, but not for tissue-detected, IL-8. IL-8 is overexpressed in CRC tissues and differentially produced by tumor or stromal components depending on CRC genetic background. Moreover, circulating IL-8 represents a strong prognostic factor in CRC, suggesting its use in the refining of prognostic CRC assessment and potentially the tailoring of therapeutic strategies in individual CRC patients.
在已成为可药物作用靶点的可溶性因子中,趋化因子白细胞介素-8(IL-8)已成为多种癌症类型中免疫治疗和靶向治疗反应的一个可能决定因素;然而,其在结直肠癌(CRC)中的预后/预测作用仍有待确定。我们:(i)对已发表的关于CRC中IL-8表达的文献进行了系统综述;(ii)搜索了公共转录组学数据库;(iii)在一系列CRC样本中研究了肿瘤细胞和浸润细胞中的IL-8表达;(iv)对已发表的将IL-8表达与CRC预后相关联的文献进行了荟萃分析。IL-8作为肿瘤/基质细胞之间双向串扰的介质具有重要作用。转录组分析表明,与正常结肠黏膜相比,CRC中特定的IL-8转录本显著过表达。此外,在我们的研究系列中,我们观察到PTEN缺失与浸润的单核细胞和肿瘤细胞的IL-8表达之间存在统计学上的显著相关性。总共有12篇论文符合我们的荟萃分析纳入标准,表明高IL-8水平与较短的总生存期和无进展生存期显著相关。敏感性分析表明,循环中的IL-8与预后高度显著相关,而组织检测到的IL-8则不然。IL-8在CRC组织中过表达,并且根据CRC的基因背景由肿瘤或基质成分差异产生。此外,循环IL-8是CRC的一个强有力的预后因素,这表明其可用于完善CRC的预后评估,并有可能为个体CRC患者量身定制治疗策略。